Nkarta, Inc. Gains FDA Alignment On Key Protocol Changes To Expand Patient Access In Ntrust-1 And Ntrust-2 Trials

Nkarta, Inc., a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies for autoimmune diseases, announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on significant protocol amendments for its ongoing Ntrust-1 and Ntrust-2 clinical trials. 

These changes are aimed at making participation easier for patients by removing the need for overnight monitoring and enabling outpatient administration of NKX019, the company’s investigational CAR-NK cell therapy. With this update, NKX019 can now be administered through community research centers and community rheumatologists, expanding trial accessibility beyond large medical institutions.

Paul J. Hastings, Chief Executive Officer of the company, explained that reaching alignment with the FDA on these enhancements is a meaningful step forward for the NKX019 clinical program. He noted that reducing the monitoring requirement from 24 hours to just 2 hours will significantly lower the burden on patients and allow more flexible participation. 

Hastings added that enabling outpatient dosing opens the door for partnerships with community rheumatology centers, which will help the company execute its clinical trials more efficiently while making advanced treatment options available to a broader range of people. The updated protocols also expand the types of patients who can be treated in the studies. 

Once the amendments complete Institutional Review Board (IRB) review and are finalized, the Ntrust-2 trial will begin enrolling patients with rheumatoid arthritis, marking an important expansion of the program into another autoimmune disease area with unmet need. In addition, both trials will now have the option to re-dose participants if necessary, providing greater flexibility to optimize individual treatment responses.

As Nkarta prepares to implement the new protocol, several important updates will follow IRB approval and final submission of the amendments. Outpatient administration will become available for both Ntrust-1 and Ntrust-2, removing the previously required overnight observation period. The option to re-dose participants will be permitted across both studies, offering an opportunity to enhance the therapeutic effect for certain patients. 

The Ntrust-2 trial will formally add a rheumatoid arthritis cohort, broadening the trial’s scope to include an additional autoimmune condition. Furthermore, all geographic monitoring requirements will be removed, further simplifying participation and reducing logistical challenges for patients.

With these changes in place, Nkarta, Inc. is positioned to advance NKX019 more efficiently, expand patient access, and strengthen the overall development pathway for its engineered NK cell therapy programs targeting autoimmune diseases.